Anyone who has used semaglutide—the active ingredient in drugs like Ozempic and Wegovy—to combat excess weight has eventually encountered an invisible wall. For the first few months, the scale consistently drops, but then an inevitable plateau sets in. Until now, this was considered a natural metabolic adaptation where the body reduces energy expenditure as weight is lost. However, the reality has proven to be far more profound, hidden within specific clusters of brain cells.
In late May 2026, a team of researchers from the U.S. National Institutes of Health (NIH) published a study in Nature Metabolism that shifts our understanding of why these plateaus occur. Using advanced fluorescence microscopy, scientists were able to observe live mouse neurons in real-time as semaglutide took effect. Their focus centered on the area postrema, a structure in the brainstem responsible for regulating appetite and the feeling of fullness.
The findings revealed that the drug's effectiveness depends directly on the concentration of an intracellular messenger called cAMP (cyclic adenosine monophosphate). When semaglutide activates receptors, cAMP levels rise, signaling the brain to suppress hunger. Yet, this response is not uniform across all cells. Scientists discovered that cellular reactions exist along a broad continuum. Some neurons rapidly dampen this internal signal, which triggers the weight-loss plateau. In essence, these cells are shielding themselves from constant external stimulation.
How can this resistance be overcome? The NIH researchers, led by Dr. Claire Gao, found a potential solution hidden within the cell itself. A natural enzyme known as phosphodiesterase-4 (PDE4) is responsible for breaking down cAMP. By blocking this enzyme's activity with an existing medical inhibitor called roflumilast, the team successfully restored the neurons' sustained sensitivity to semaglutide. The satiety signal no longer faded away.
Looking ahead, this discovery paves the way for the development of combination therapies. Modulating the cAMP molecule could not only break through the ‘plateau effect’ but also reduce the required frequency of injections. Rather than indefinitely increasing the dosage of the primary hormonal drug, medicine may soon be able to precisely manage the internal switches of the cells. While the journey from lab mice to pharmacy shelves will take years, the trajectory for the obesity treatment industry has been more clearly defined.
